Profile

Cagen Ltd

Cagen has developed self-assembling protein nanocages which can be used to carry drugs within the body.

These nanocages can protect payloads from premature degradation or excess toxicity until they reach the target site. They can also improve the bioavailability of molecules, enabling access to novel therapeutic approaches. By controlling drug release, protein nanocages could improve the safety and toxicity profiles of compounds that have previously failed development, allowing companies to revisit these candidates.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Relevant News

UKI2S announces seed investment in Cagen, a pioneering synthetic biology company using protein nanocages

UK Innovation & Science Seed Fund (UKI2S) and Imperial Innovations announce the launch of Cagen,…

read more

Blog

Is Your Business Plan Hitting The Mark For Investors?

Midven explores how SMEs effectively communicate high growth potential to attract investors and take...

read more

Midven Director and MEIF Fund Principal, Roger Wood, starts 2020...

Having been launched in 2018, the Midlands Engine Investment Fund comprises a range of...

read more

More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×